Julien Hadoux, Rossella Elisei, Marcia S Brose, Ana O Hoff, Bruce G Robinson, Ming Gao, Barbara Jarzab, Pavel Isaev, Katerina Kopeckova, Jonathan Wadsley, Dagmar Führer, Bhumsuk Keam, Stéphane Bardet, Eric J Sherman, Makoto Tahara, Mimi I Hu, Ravinder Singh, Yan Lin, Victoria Soldatenkova, Jennifer Wright, Boris Lin, Patricia Maeda, Jaume Capdevila, Lori J Wirth
BACKGROUND: Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in advanced RET -mutant medullary thyroid cancer in a phase 1-2 trial, but its efficacy as compared with approved multikinase inhibitors is unclear. METHODS: We conducted a phase 3, randomized trial comparing selpercatinib as first-line therapy with the physician's choice of cabozantinib or vandetanib (control group). Eligible patients had progressive disease documented within 14 months before enrollment...
November 16, 2023: New England Journal of Medicine